Physician

Mohammed Nawaf Kanaan

According to 2025 Medicare claims, Mohammed Kanaan (NPI: 1326270992) practices hematology/oncology in the Tacoma-Lakewood, WA market, with the plurality of this provider's patient population coming from Pierce, WA. This provider's primary affiliated billing organization is NORTHWEST MEDICAL SPECIALTIES PLLC (NPI: 1548261308; TIN: 911867315) and primary practice location at 98373-1659. Kanaan is affiliated with the CommonSpirit ACO I (ACO ID: A2164), participating under the MSSP model.

Kanaan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 505 traditional Medicare patients, billed 88,468 HCPCS/CPT codes, and received $1,849,121 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 726 prescription claims across 138 beneficiaries totaling $2,487,599 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 62 claims. Open Payments data shows 30 records totaling $4,709,312. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $23,389 to $1,849,121. Similarly, Part D prescription costs have risen steadily, from $7,687 to $2,487,599. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,435 to $1,745.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	91	332	$23,389
2016	226	1,075	$63,580
2017	169	995	$81,471
2018	188	1,158	$80,246
2019	291	4,312	$66,540
2020	513	76,746	$706,377
2021	642	93,861	$1,280,223
2022	473	89,039	$1,448,296
2023	511	126,888	$1,624,758
2024	505	88,468	$1,849,121

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	49	178	$7,687
2016	146	1,737	$99,716
2017	152	1,608	$146,155
2018	106	980	$138,114
2019	87	530	$41,336
2020	98	317	$533,392
2021	112	457	$1,411,576
2022	153	909	$2,511,036
2023	137	932	$2,501,737
2024	138	726	$2,487,599

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	13	213	$10,973
2017	N/R	105	$1,957
2018	N/R	95	$6,901
2019	N/R	62	$1,946
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	236	596	$96
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	171	341	$13
80053	Blood test, comprehensive group of blood chemicals	140	469	$10
36415	Insertion of needle into vein for collection of blood sample	216	700	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	211	679	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	45	1,239	$938,022
Lenalidomide	Lenalidomide	21	560	$286,292
Ibrance	Palbociclib	17	476	$271,175
Calquence	Acalabrutinib Maleate	12	360	$176,600
Abiraterone Acetate	Abiraterone Acetate	88	2,640	$155,644

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$180	Tempus AI, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	25	$4,709,132	Aveo Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammed Nawaf Kanaan?

Tedicare shows public-source Medicare data for Mohammed Nawaf Kanaan (NPI 1326270992), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammed Nawaf Kanaan have ACO affiliation data?

Mohammed Nawaf Kanaan is shown with ACO affiliation data for CommonSpirit ACO I (MSSP, ACO ID A2164).

What billing organization is linked to Mohammed Nawaf Kanaan?

Mohammed Nawaf Kanaan is linked to NORTHWEST MEDICAL SPECIALTIES PLLC (billing NPI 1548261308) in the available physician profile data.

Does Mohammed Nawaf Kanaan have Open Payments data?

Mohammed Nawaf Kanaan has 30 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.